Table 3.
Sensitivity analysis.
| Outcome | Subgroup | No. studies | OR (95% CI) | I 2 | p heterogeneity |
|---|---|---|---|---|---|
| All-cause death | RCTs | 5 | 0.68 (0.51–0.91) | 4.4% | 0.381 |
| PSM studies | 6 | 0.86 (0.77–0.96) | 58.0% | 0.036 | |
| Long-term | 5 | 0.84 (0.72–0.98) | 0% | 0.410 | |
| Midterm | 6 | 0.81 (0.70–0.95) | 66.9% | 0.010 | |
| MVD | 9 | 0.86 (0.77–0.95) | 45.6% | 0.065 | |
| DES exclusively | 5 | 0.72 (0.54–0.97) | 73.8% | 0.004 | |
| Short-term death | RCTs | 2 | 1.45 (0.27–7.80) | 29.7% | 0.233 |
| PSM studies | 2 | 0.77 (0.41–1.44) | 69.5% | 0.070 | |
| Long-term | 1 | 3.90 (0.43–35.26) | N/A | N/A | |
| Midterm | 3 | 0.76 (0.46–1.24) | 39.2% | 0.193 | |
| MVD | 2 | 0.77 (0.41–1.44) | 69.5% | 0.070 | |
| DES exclusively | 4 | 0.84 (0.48–1.47) | 44.5% | 0.144 | |
| Myocardial infarction | RCTs | 5 | 0.50 (0.26–0.97) | 58.1% | 0.049 |
| PSM studies | 4 | 0.35 (0.20–0.63) | 90.5% | <0.001 | |
| Long-term | 5 | 0.35 (0.23–0.55) | 40.6% | 0.151 | |
| Midterm | 4 | 0.46 (0.22–0.96) | 86.3% | <0.001 | |
| MVD | 7 | 0.37 (0.23–0.60) | 84.1% | <0.001 | |
| DES exclusively | 5 | 0.42 (0.23–0.74) | 84.2% | <0.001 | |
| Stroke | RCTs | 4 | 1.05 (0.55–2.00) | 26.7% | 0.251 |
| PSM studies | 3 | 1.49 (1.18–1.90) | 0% | 0.368 | |
| Long-term | 3 | 0.92 (0.37–2.25) | 49.2% | 0.140 | |
| Midterm | 4 | 1.49 (1.18–1.88) | 0% | 0.567 | |
| MVD | 5 | 1.33 (0.94–1.90) | 31.4% | 0.212 | |
| DES exclusively | 5 | 1.48 (1.18–1.86) | 0% | 0.459 | |
| Repeat revascularization | RCTs | 4 | 0.33 (0.24–0.47) | 0% | 0.484 |
| PSM studies | 4 | 0.19 (0.09–0.38) | 94.3% | <0.001 | |
| Long-term | 4 | 0.24 (0.19–0.29) | 0% | 0.500 | |
| Midterm | 4 | 0.23 (0.08–0.63) | 92.1% | <0.001 | |
| MVD | 6 | 0.21 (0.12–0.36) | 90.6% | <0.001 | |
| DES exclusively | 5 | 0.27 (0.14–0.53) | 89.2% | <0.001 |
CI, confidence interval; DES, drug-eluting stent; MVD, multivessel disease; OR, odds ratio; PSM, propensity-score matched; RCT, randomized controlled trial.